Abstract
To address concerns about the long-term safety of using dopamine agonists to treat patients with hyperprolactinemia Valassi and colleagues carried out a systematic review of the literature. Although the results show no increased risk of valvular heart disease, lengthy prospective follow-up studies are needed in patients requiring long-term high dose regimens.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature clinical practice. Endocrinology & metabolism
Paper Title
Journal
Date
